论文部分内容阅读
目的 观察非手术治疗、栓塞术和手术前后血清β－ 葡萄糖醛酸酶（β－ Ｇ） 活性变化。方法 应用ＥＬＩＳＡ 技术对５２ 例肝细胞癌病人不同治疗方法前后血清β－ Ｇ 活性进行测定。结果 肝癌病人血清中β－ Ｇ 活性滴度（１７．２ ±２．４） 明显高于正常对照组（６．５ ±１．３） ， Ｐ ＜ ０．０１ ；其中１２ 例保守治疗病人治疗前（１７．０ ±２．３） 与治疗后（１６．５ ±１．９） 无明显变化， Ｐ ＞ ０．０５ ；１５ 例栓塞介入治疗前β－ Ｇ 活性滴度（１７．４ ±２．３） 与治疗后（１０．６ ±１．８） 有显著性差异， Ｐ ＜ ０．０１ ；２５ 例手术治疗病人，术后活性滴度（９．９ ±２．０） 明显低于术前（１７．１ ±２．４） ， Ｐ ＜０．０１ 。比较手术病人β－ Ｇ 活性与肿瘤大小及淋巴结转移无关，与组织恶性程度呈正相关。结论 β－ Ｇ 作为体内活性酶，其变化对肝癌的诊断、治疗及病程判定有一定的参考价值。
Objective To observe the changes of serum β-glucuronidase (β-G) activity before and after non-surgical treatment, embolization and surgery. Methods The serum β-G activity of 52 patients with hepatocellular carcinoma before and after different treatments was measured by ELISA. Results The serum β-G activity titer (17.2 ± 2.4) was significantly higher in liver cancer patients than in the normal control group (6.5 ± 1.3), P <0.01; 12 patients were treated conservatively before treatment. (17.0 ± 2.3) and after treatment (16.5 ± 1.9) no significant change, P> 0.05; 15 patients before embolization interventional treatment β-G activity titer (17.4 ± 2). 3) There was a significant difference (P < 0.01) with post-treatment (10.6 ± 1.8); in 25 patients treated with surgery, postoperative activity titer (9.9 ± 2.0) was significantly lower than preoperative (17.1 ±2.4), P <0.01. The β-G activity in surgical patients was not associated with tumor size and lymph node metastasis, but was positively correlated with the degree of malignancy. Conclusion β-G is an active enzyme in vivo, and its changes have certain reference value for the diagnosis, treatment and disease course determination of liver cancer.